Tokenized Access to Colossal Biosciences Pre-IPO Equity.

Colossal is a genetics + computational biology company commercializing a “de-extinction” and conservation-genomics platform using CRISPR, reproductive tech, and large-scale bioinformatics to build capabilities that can translate beyond headline species. In January 2025, Colossal announced a $200M Series C led by TWG Global (Mark Walter & Thomas Tull) at a $10.2B valuation, bringing total funding to $435M since launch. The company is also building real-world deployment credibility via the Colossal Foundation, which it says supports 48 conservation partners globally. For investors, this is exposure to a high-profile synthetic biology platform with deep-pocketed backers, expanding scientific infrastructure, and multiple downstream commercialization paths (genetic rescue, species preservation, and related biotech tooling).